Skip to main content
. 2016 Jan 4;127(10):1269–1275. doi: 10.1182/blood-2015-10-674242

Figure 1.

Figure 1

Analysis of major cytogenetic and molecular responses (≤10% or ≤1%) for BCR-ABL at 3 and 6 months according to the type of BCR-ABL transcript (e13a2, e14a2, or both). (A) Achievement of MCyR (≤35% Ph-positive metaphases). (B) Achievement of molecular response (≤1% and ≤10% BCR-ABL-IS) at 3 and 6 months. Percentages are shown at the top, and the absolute numbers of evaluable patients are shown at the bottom of each graph. (C) Pattern of changes in median BCR-ABL transcript levels (IS) over time (3, 6, 12, 18, 24, 36, and 60 months) according to the type of BCR-ABL transcript (log scale). IS, international scale.